|
2022 Journal Article The PO4-tential for less toxic CAR T-cell therapiesTobin, Joshua W.D., Green, Michael R. and Gandhi, Maher K. (2022). The PO4-tential for less toxic CAR T-cell therapies. Cancer Immunology Research, 10 (12), 1422-1422. doi: 10.1158/2326-6066.cir-22-0793 |
|
2022 Journal Article Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases RegistryLymphoma and Related Diseases Registry Investigators, Gandhi, Maher K. and Keane, Colm (2022). Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry. BMC Medical Research Methodology, 22 (1) 266, 1-10. doi: 10.1186/s12874-022-01728-0 |
|
2022 Conference Publication Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin LymphomaGunawardana, Jay, Law, Soi C., Sabdia, Muhammed B., Bednarska, Karolina, Brosda, Sandra, Zaharia, Andreea, Tsang, Hennes, de Long, Lilia M., Burgess, Melinda, Talaulikar, Dipti, Lee, Justina N., Jude, Emily, Hawkes, Eliza A., Jain, Sanjiv, Nath, Karthik, Gould, Clare, Swain, Fiona, Tobin, Joshua W. D., Keane, Colm, Birch, Simone, Shanavas, Mohamed, Snell, Cameron and Gandhi, Maher K. (2022). Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma. Third AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application, 23-25 June 2022, Boston, MA USA. Philadelphia, PA USA: American Association for Cancer Research. doi: 10.1158/2643-3249.lymphoma22-a17 |
|
2022 Journal Article CD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin LymphomaGandhi, Maher K and Keane, Colm (2022). CD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin Lymphoma. Haematologica, 108 (4), 1-3. doi: 10.3324/haematol.2022.281440 |
|
2022 Journal Article Neoantigens: the next frontier in precision immunotherapy for B-cell lymphoproliferative disordersSabdia, Muhammed B., Patch, Ann-Marie, Tsang, Hennes and Gandhi, Maher K. (2022). Neoantigens: the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders. Blood Reviews, 56 100969, 100969. doi: 10.1016/j.blre.2022.100969 |
|
2022 Journal Article Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphomaMa, Man Chun John, Tadros, Saber, Bouska, Alyssa, Heavican, Tayla, Yang, Haopeng, Deng, Qing, Moore, Dalia, Akhter, Ariz, Hartert, Keenan, Jain, Neeraj, Showell, Jordan, Ghosh, Sreejoyee, Street, Lesley, Davidson, Marta, Carey, Christopher, Tobin, Joshua, Perumal, Deepak, Vose, Julie M., Lunning, Matthew A., Sohani, Aliyah R., Chen, Benjamin J., Buckley, Shannon, Nastoupil, Loretta J., Davis, R. Eric, Westin, Jason R., Fowler, Nathan H., Parekh, Samir, Gandhi, Maher, Neelapu, Sattva ... Green, Michael R. (2022). Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica, 107 (3), 690-701. doi: 10.3324/haematol.2020.274258 |
|
2021 Conference Publication The NLPHL Tumor Microenvironment Is Markedly Enriched in the Tigit and PD-1 Signalling Axes Compared to Classical Hodgkin LymphomaGunawardana, Jay, Sabdia, Muhammed B., Bednarska, Karolina, Law, Soi C., Brosda, Sandra, Tsang, Hennes, De Long, Lilia Merida, Zaharia, Andreea, Lee, Justina, Jude, Emily, Hawkes, Eliza, Nath, Karthik, Gould, Clare, Burgess, Melinda Lea, Swain, Fiona, Tobin, Joshua W. D., Keane, Colm, Birch, Simone, Talaulikar, Dipti, Jain, Sanjiv, Shanavas, Mohamed, Snell, Cameron and Gandhi, Maher (2021). The NLPHL Tumor Microenvironment Is Markedly Enriched in the Tigit and PD-1 Signalling Axes Compared to Classical Hodgkin Lymphoma. 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2021-145840 |
|
2021 Conference Publication Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 StudyTrotman, Judith, Presgrave, Peter, Carradice, Duncan P., Lenton, Douglas Stuart, Gandhi, Maher, Cochrane, Tara, Badoux, Xavier, NKhoma, Gloria, Butcher, Belinda, Fulham, Michael and Johnston, Anna (2021). Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study. 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2021-146343 |
|
2021 Journal Article Immunity reloaded: deconstruction of the PD-1 axis in B cell lymphomasBednarska, Karolina, Nath, Karthik, Nicol, William and Gandhi, Maher K. (2021). Immunity reloaded: deconstruction of the PD-1 axis in B cell lymphomas. Blood Reviews, 50 100832, 100832. doi: 10.1016/j.blre.2021.100832 |
|
2021 Journal Article Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapyShanavas, Mohamed, Law, Soi‐Cheng, Hertzberg, Mark, Hicks, Rodney J., Seymour, John F., Li, Zhixiu, Merida de Long, Lilia, Nath, Karthik, Sabdia, Muhammed B., Gunawardana, Jay, Gandhi, Maher K. and Keane, Colm (2021). Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy. Clinical and Translational Immunology, 10 (11) e1351, e1351. doi: 10.1002/cti2.1351 |
|
2021 Journal Article Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic targetGould, Clare, Lickiss, Jennifer, Kankanige, Yamuna, Yerneni, Satwica, Lade, Stephen, Gandhi, Maher K., Chin, Collin, Yannakou, Costas K., Villa, Diego, Slack, Graham W., Markham, John F., Tam, Constantine S., Nelson, Niles, Seymour, John F., Dickinson, Michael, Neeson, Paul J., Westerman, David and Blombery, Piers (2021). Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target. British Journal of Haematology, 195 (1) bjh.17789, 113-118. doi: 10.1111/bjh.17789 |
|
2021 Journal Article Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphomaNath, Karthik, Law, Soi-Cheng, Sabdia, Muhammed B., Gunawardana, Jay, de Long, Lilia M., Sester, David, Shanavas, Mohamed, Tsang, Hennes, Tobin, Joshua W. D., Halliday, Sarah-Jane, Hernandez, Annette, Cross, Donna, Bird, Robert J., Jain, Sanjiv, Keane, Colm, Talaulikar, Dipti, Trotman, Judith, Law, Phillip and Gandhi, Maher K. (2021). Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma. Blood Advances, 5 (12), 2644-2649. doi: 10.1182/bloodadvances.2020004051 |
|
2021 Journal Article Successful treatment of Epstein–Barr virus–associated primary central nervous system lymphoma due to post‐transplantation lymphoproliferative disorder, with ibrutinib and third‐party Epstein–Barr virus–specific T cellsLaw, Soi C., Hoang, Thanh, O'Rourke, Kacey, Tobin, Joshua W. D., Gunawardana, Jay, Loo‐Oey, Dorothy, Bednarska, Karolina, Merida de Long, Lilia, Sabdia, Muhammed B., Hapgood, Greg, Blyth, Emily, Clancy, Leighton, Hennig, Stefanie, Keane, Colm and Gandhi, Maher K. (2021). Successful treatment of Epstein–Barr virus–associated primary central nervous system lymphoma due to post‐transplantation lymphoproliferative disorder, with ibrutinib and third‐party Epstein–Barr virus–specific T cells. American Journal of Transplantation, 21 (10) ajt.16628, 3465-3471. doi: 10.1111/ajt.16628 |
|
2021 Conference Publication Intratumoral T‐cells Have A Differential Impact On FDG‐PET Parameters In Follicular LymphomaNath, K., Law, Soi‐C., Talaulikar, D., Sabdia, M. B., Gunawardana, J., de Long, L. M., Shanavas, M., Tsang, H., Tobin, J. W., Halliday, S.‐J., Hernandez, A., Cross, D., Bird, R., Jain, S., Keane, C., Trotman, J., Law, P. and Gandhi, M. K. (2021). Intratumoral T‐cells Have A Differential Impact On FDG‐PET Parameters In Follicular Lymphoma. 16th International Conference on Malignant Lymphoma, Online, 18–22 June 2021. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.76_2879 |
|
2021 Journal Article Discordant solutions to discordant problemsTobin, Joshua W. D. and Gandhi, Maher K. (2021). Discordant solutions to discordant problems. Blood, 137 (21), 2857-2858. doi: 10.1182/blood.2021011362 |
|
2021 Journal Article EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entityGandhi, Maher K., Hoang, Thanh, Law, Soi C., Brosda, Sandra, O'Rourke, Kacey, Tobin, Joshua W. D., Vari, Frank, Murigneux, Valentine, Fink, J. Lynn, Gunawardana, Jay, Gould, Clare M., Oey, Harald, Bednarska, Karolina, Delecluse, Susanne, Trappe, Ralf Ulrich, de Long, Lilia Merida, Sabdia, Muhammed Bilal, Bhagat, Govind, Hapgood, Greg, Blyth, Emily, Clancy, Leighton E., Wight, Joel, Hawkes, Eliza A., Rimsza, Lisa M., Maguire, Alanna, Bojarczuk, Kamil, Chapuy, Bjoern and Keane, Colm (2021). EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood, 137 (11), 1468-1477. doi: 10.1182/blood.2020008520 |
|
2021 Journal Article Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experienceLewis, Katharine L., Chin, Collin K., Manos, Kate, Casey, John, Hamad, Nada, Crawford, Julie, Ho, Shir-Jing, Issa, Samar, Grigg, Andrew, Wood, Peter, Gandhi, Maher K., Do, Bryan, Nastoupil, Loretta, Hawkes, Eliza A. and Cheah, Chan Y. (2021). Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. British Journal of Haematology, 192 (6) bjh.16946, 1049-1053. doi: 10.1111/bjh.16946 |
|
2021 Journal Article Targeted treatment of follicular lymphomaNath, Karthik and Gandhi, Maher K. (2021). Targeted treatment of follicular lymphoma. Journal of Personalized Medicine, 11 (2) 152, 1-22. doi: 10.3390/jpm11020152 |
|
2021 Journal Article A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphomaTobin, Joshua W. D., Crothers, Anna, Ma, Ti Eric, Mollee, Peter, Gandhi, Maher K., Scuffham, Paul and Hapgood, Greg (2021). A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma. Leukemia and Lymphoma, 62 (14), 1-9. doi: 10.1080/10428194.2021.1957866 |
|
2021 Journal Article Tumor microenvironment of follicular lymphomaNath, Karthik, Tsang, Hennes and Gandhi, Maher K. (2021). Tumor microenvironment of follicular lymphoma. Annals of Lymphoma, 5, 1-19. doi: 10.21037/aol-20-55 |
